JOLT HEALTH INC. ANNOUNCES CLOSING
JOLT HEALTH INC. ANNOUNCES CLOSING
VANCOUVER, BC, CANADA, July 10, 2023 (GLOBE NEWSWIRE) -- Jolt Health Inc. ("JOLT" and or "the Company") (CSE:JOLT) (FSE: G1Q0) announced as per CSE policy, that is intends to close its previously announced non-brokered private placement financing on July 15th, 2023. The company will issue a total 6,984,266 units for gross proceeds of $100,125 at $0.0143 per unit. Each unit consists of one common share and one common share warrant. Each warrant entitles the holder to subscribe for one additional common share for a period of 2 years from the date of closing at a price of $0.05, subject to the Corporation's option to accelerate the expiry date if the stock trades at $0.15 for 10 trading days.
加拿大不列颠哥伦比亚省温哥华,2023年7月10日(GLOBE NEWSWIRE)— Jolt Health Inc.(“JOLT” 和/或 “公司”)(CSE: JOLT)(FSE:G1Q0) 根据CSE政策宣布,计划于7月15日结束先前宣布的非经纪私募融资第四,2023。该公司将发行总额为6,984,266个单位,总收益为100,125美元,每单位0.0143美元。每个单位由一股普通股和一份普通股权证组成。每份认股权证都使持有人有权从收盘之日起两年内以0.05美元的价格再认购一股普通股,前提是如果股票在10个交易日内以0.15美元的价格交易,则公司可以选择加快到期日。
The company will pay finders fees of $1,125.25 and issue 87,500 brokers warrants in accordance with closing.
该公司将向发现者支付1,125.25美元的费用,并根据收盘价发行87,500份经纪人认股权证。
About Jolt Health Inc.
关于 Jolt Health Inc.
Jolt Health Inc. (CSE – JOLT) is a leading life sciences company focused on healthcare, biotechnology and artificial intelligence. The company currently holds exclusive licenses for innovative therapeutic and pharmaceutical products throughout Europe, the UK, and North America. The company is committed to transforming the industry through research, collaboration, and technological advancement, shaping the future of healthcare worldwide.
Jolt Health Inc.(CSE — JOLT)是一家领先的生命科学公司,专注于医疗保健、生物技术和人工智能。该公司目前在欧洲、英国和北美拥有创新治疗和药品的独家许可。该公司致力于通过研究、合作和技术进步来改变行业,塑造全球医疗保健的未来。
For further information, please contact:
欲了解更多信息,请联系:
Investor Relations
投资者关系
Telephone: 1 (604) 343-2977
电话:1 (604) 343-2977
E-mail: info@jolt-health.com
电子邮件:info@jolt-health.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大证券交易所及其监管服务提供商(该术语在加拿大证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。
Forward Looking Statements
前瞻性陈述
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID–19, including the impact of COVID–19 on the Company's business, financial condition and results of operations, lack of investor demand for Bitcoin and/or Bitcoin futures exchange traded funds, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.
本新闻稿中列出的某些信息可能包含前瞻性陈述,涉及重大的已知和未知风险和不确定性。除历史事实陈述外,所有陈述均为前瞻性陈述,包括但不限于有关公司或涉及公司的未来财务状况、业务战略、所得款项使用、企业愿景、拟议收购、合作伙伴关系、合资企业和战略联盟及合作、预算、成本以及计划和目标的陈述。此类前瞻性信息反映了管理层当前的信念,并基于管理层目前可用的信息。通常,前瞻性陈述可以通过使用 “计划”、“期望”、“预期”、“预期”、“预算”、“预期”、“估计”、“预测”、“预测”、“打算”、“目标”、“目标”、“目标”、“预期”、“可能” 或 “相信” 等词语或此类单词和短语的变体(包括负面变体)来识别,也可以通过陈述来识别效果是 “可以”、“可以”、“应该”、“将”、“可以” 或 “将” 采取、发生或实现的某些行动。许多已知和未知的风险、不确定性和其他因素可能导致实际业绩或表现与前瞻性信息所表达或暗示的任何未来业绩或表现存在重大差异。这些前瞻性陈述受到许多风险和不确定性的影响,其中某些风险和不确定性是公司无法控制的,包括但不限于总体经济状况的影响、行业状况、与COVID-19等流行病或流行病相关的风险,包括COVID—19对公司业务、财务状况和经营业绩的影响、投资者对比特币和/或比特币期货交易所交易基金缺乏需求以及对监管部门批准的依赖。提醒读者,在准备此类信息时使用的假设虽然在准备时被认为是合理的,但可能被证明是不准确的,因此,不应过分依赖前瞻性陈述。除非证券法要求,否则公司不承担任何更新或修改其前瞻性陈述的义务,无论是由于新信息、未来事件还是其他原因。
CONTACT: Investor Relations Jolt Health Inc. 1 (604) 343-2977 investors@love-pharma.com
联系人:投资者关系 Jolt Health Inc. 1 (604) 343-2977 investors@love-pharma.com